{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:07Z","timestamp":1792508587244,"version":"4.5.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.1080\/10428194.2023.2262066","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:42:55Z","timestamp":1697424175000},"page":"2269-2278","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed\/refractory follicular lymphoma in third or subsequent lines of systemic therapy"],"prefix":"10.1080","volume":"64","author":[{"given":"Sarah F.","family":"McGough","sequence":"first","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Shamas","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Jaber","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binay","family":"Swarup","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Blanchet Zumofen","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Lauti\u00e9","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Parreira","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Shewade","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,15]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148809"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24200"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00200-5"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00315"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.915342"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135839"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_5_14_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022 [cited 2023 Jan 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01749-5"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1586"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00149"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145872"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765"},{"key":"e_1_3_5_24_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-cell Lymphomas V.4.2022. \u00a9 National Comprehensive Cancer Network Inc. 2022. All rights reserved. Accessed January 18 2023. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_5_25_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-cell Lymphomas V.5.2023. \u00a9 National Comprehensive Cancer Network Inc. 2023. All rights reserved. Accessed August 15 2023. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01659-0"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12090"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0019623"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_5_31_1","unstructured":"R-Project. The R Project for Statistical Computing. 2023 [cited 2023 Jan 6]. Available from: https:\/\/www.R-project.org\/."},{"key":"e_1_3_5_32_1","unstructured":"Prescribing information for ALIQOPA (copanlisib). 2017 cited 2023 Jan 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf."},{"key":"e_1_3_5_33_1","unstructured":"Prescribing information for TAZVERIK (tazemetostat). 2020 [cited 2023 Jan 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf."},{"key":"e_1_3_5_34_1","unstructured":"Prescribing information for YESCARTA (axicabtagene ciloleucel). 2022 [cited 2023 Jan 6]. Available from: https:\/\/ce.mayo.edu\/sites\/default\/files\/yescarta-pi.pdf."},{"key":"e_1_3_5_35_1","unstructured":"Prescribing information for KYMRIAH (tisagenlecleucel). 2022 cited 2023 Jan 6]. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kymriah.pdf."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.06.011"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2262066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T11:07:37Z","timestamp":1727262457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2262066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,12,6]]}},"alternative-id":["10.1080\/10428194.2023.2262066"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2262066","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}